Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

NCT05228015 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

67

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor strategic reasons

Conditions

Solid Tumors, Adult
Solid Tumor
Malignant Pleural Mesothelioma (MPM)
Epithelioid Hemangioendothelioma (EHE)
NF2 Deficient Mesothelioma
Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes
NF2 Deficiency
YAP1 or TAZ Gene Fusions

Interventions

DRUG: IK-930
DRUG: Osimertinib

Sponsor

Ikena Oncology